Aptose Biosciences Inc. Material Event - What Happened (Acquisition by Hanmi Pharmaceutical)

1. What happened? (in plain English - the actual event)

Aptose Biosciences is a biotech company. It develops new treatments for blood cancers and solid tumors. They recently announced big news: Hanmi Pharmaceutical Co. Ltd. is buying them. Hanmi will buy all Aptose shares it doesn't own. The price is $0.30 per share in cash. This price is much higher than Aptose's stock traded before the announcement. Hanmi is a top South Korean drug company. It already owned about 19.9% of Aptose's stock.

To help the deal pass, Glass, Lewis & Co. (Glass Lewis) made a recommendation. This important firm advises large investors on how to vote. They officially told Aptose shareholders to vote "FOR" the acquisition. Their advice matters a lot. Many big investors use their analysis to decide how to vote.

2. When did it happen?

Glass Lewis announced its recommendation on March 23, 2026. Shareholders must vote on this deal by 11:00 a.m. (EST) on Friday, March 27, 2026. The final vote count happens at a special meeting on March 31, 2026. They will announce the results then.

3. Why did it happen? (context and background)

The company didn't provide much detail about why Hanmi is buying Aptose in their filing. But it's a strategic move with several reasons. Aptose's own Board of Directors and a special committee of independent directors have unanimously recommended that shareholders approve the deal. They recommended it after a thorough review. This included financial and legal advice. They believe it's the best path for the company and shareholders. It offers sure value right away.

Acquisitions like this often happen for a few reasons:

• Strategic Fit: A bigger company like Hanmi sees value in a smaller company like Aptose. This could be its drug projects, technology, or know-how. Aptose's main drug, TUS (tuspetinib), is a pill taken daily. It's in early human trials (Phase 1/2) for a type of blood cancer called AML. Hanmi likely sees TUS and Aptose's other early-stage drugs as a good fit. They can add to Hanmi's cancer drug lineup. This also helps Hanmi grow globally and boost its research.
• Securing the Future: Biotech is expensive and risky. Being bought can give a company more money and stability. It offers a clearer way to get drugs to patients. Aptose, like many small drug developers, struggled to get long-term funding. This deal gives shareholders a clear way out. It also ensures Aptose's drugs keep developing under a company with more money.

4. Why does this matter? (impact and significance)

This is a HUGE deal for Aptose and its shareholders. If approved, Aptose Biosciences Inc. will stop being an independent public company. It will become fully owned by Hanmi Pharmaceutical.

• End of an Era: Aptose will no longer operate as its own company. Its shares will stop trading independently.
• Shareholder Payout: Shareholders will get $0.30 per share in cash. The stock will stop trading on the Toronto Stock Exchange (TSX) or OTCQX Best Market. This gives shareholders cash right away. It also provides a clear return on their investment.
• Future of Drugs: Hanmi will now control Aptose's drug development. This includes its main drug, TUS. Hanmi's money and setup could speed up drug development. Or, Hanmi might change which drugs it focuses on.

5. Who is affected? (employees, customers, investors, etc.)

• Investors (that's you!): You are the most affected group. You must decide whether to vote "FOR" the acquisition. If it passes, you'll get $0.30 per share in cash. Aptose stock will eventually be removed from the stock exchange. This means you won't own shares in an independent Aptose anymore.
• Aptose Biosciences Inc. itself: The company will stop operating independently. Hanmi Pharmaceutical will absorb its operations, research, and employees. This change will bring big administrative and operational shifts.
• Employees: Acquisitions often mean changes. Teams might combine, and some jobs could overlap. Employees will work under Hanmi's rules and structure. They might get new resources and career chances in a bigger company.
• Patients: Hanmi will now guide Aptose's drug development. This includes its main drug, TUS for AML. This could mean more money for development. It might speed up trials and get treatments to patients faster. Or, Hanmi might change which treatments it prioritizes.

6. What happens next? (immediate and future implications)

• Shareholder Vote: Shareholders must vote by March 27, 2026. The final meeting is on March 31, 2026. Most shareholder votes usually need to be "FOR" the deal to pass.
• Approvals: Even with shareholder approval, other groups must agree. This includes the Court of King's Bench of Alberta. Aptose is a Canadian company, so this court must approve. The Toronto Stock Exchange (TSX) must also approve its removal from trading. Other standard approvals might be needed too.
• Deal Closure: The acquisition will close if all approvals happen. This should be soon after shareholder and court approvals. Then, Aptose shareholders will get $0.30 per share in cash. Hanmi will absorb the company.
• Delisting: Aptose's stock will eventually stop trading on the TSX and OTCQX Best Market. This usually happens a few business days after the deal closes.

7. What should investors/traders know? (practical takeaways)

• Your Vote Matters: If you own Aptose shares, understand the deal terms. Cast your vote by the March 27, 2026 deadline. The company hired Morrow Sodali to help with questions and voting. (Contact info is in the official filing).
• Cash Payout: If the deal closes, you will get $0.30 per share in cash. This payment is taxable. Talk to a tax advisor about how it affects your taxes.
• End of Independent Trading: This acquisition is likely Aptose's last big event as an independent public company. Don't expect the stock to trade much longer if the deal passes. It will be removed from the TSX and OTCQX.
• Risk of Deal Failure: Glass Lewis and the board recommend the deal. But it could still fail. Unexpected problems, regulatory issues, or shareholder disapproval could stop it. If the deal fails, the stock price could fall a lot. This would reflect losing the deal's extra value. It would also bring back uncertainty about Aptose's future and funding.
• Not Financial Advice: This information helps you understand the situation. Always do your own research. Read the official proxy statement for full details. It includes advice from financial experts. Or, talk to a financial advisor before making any investment decisions.